Brokerages Set Jasper Therapeutics, Inc. (NASDAQ:JSPR) Price Target at $74.86

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have been given an average rating of “Buy” by the nine research firms that are covering the firm, MarketBeat.com reports. Nine analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have issued a report on the stock in the last year is $74.86.

A number of analysts have recently issued reports on JSPR shares. HC Wainwright reiterated a “buy” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research note on Thursday, October 24th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Jasper Therapeutics in a report on Monday, September 9th. Evercore ISI restated an “outperform” rating and set a $65.00 price objective on shares of Jasper Therapeutics in a research note on Monday, August 26th. Royal Bank of Canada decreased their price objective on shares of Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating for the company in a report on Wednesday, August 14th. Finally, JMP Securities reaffirmed a “market outperform” rating and issued a $70.00 price target on shares of Jasper Therapeutics in a report on Tuesday, October 15th.

Jasper Therapeutics Stock Performance

JSPR stock opened at $22.10 on Tuesday. Jasper Therapeutics has a one year low of $4.00 and a one year high of $31.01. The stock has a market capitalization of $333.71 million, a P/E ratio of -4.66 and a beta of 2.19. The company has a 50 day moving average price of $20.21 and a two-hundred day moving average price of $20.97.

Jasper Therapeutics (NASDAQ:JSPR) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.09) by $0.12. Research analysts forecast that Jasper Therapeutics will post -4.47 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Jasper Therapeutics

A number of large investors have recently made changes to their positions in the company. Braidwell LP acquired a new position in Jasper Therapeutics in the 3rd quarter worth about $9,091,000. Ally Bridge Group NY LLC increased its holdings in shares of Jasper Therapeutics by 82.7% in the third quarter. Ally Bridge Group NY LLC now owns 399,466 shares of the company’s stock valued at $7,514,000 after purchasing an additional 180,852 shares in the last quarter. StemPoint Capital LP acquired a new position in Jasper Therapeutics during the 1st quarter valued at about $3,794,000. Ikarian Capital LLC acquired a new stake in Jasper Therapeutics during the 1st quarter worth $3,088,000. Finally, Russell Investments Group Ltd. bought a new position in shares of Jasper Therapeutics in the 1st quarter worth $2,343,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.